CS
AXSM icon

Credit Suisse’s Axsome Therapeutics AXSM Stock Holding History

Credit Suisse’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-500
Closed -$34K – 4388
2021
Q2 		$34K Buy
+500
New +$30K ﹤0.01% 4410

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's AXSM Position: Q1 2024 in Review

Credit Suisse reduced its Axsome Therapeutics (AXSM) stake by 0.82% in Q1 2024, selling an estimated $30.4K and leaving 43,721 shares worth $3.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1506.

Credit Suisse first reported a position in AXSM in Q2 2017 and has held it in 21 quarters since. The position peaked at $4.62M in Q4 2021. 260 funds tracked by Wall St. Rank hold AXSM as of Q1 2024.

  • Credit Suisse held 43,721 shares of Axsome Therapeutics worth $3.49M as of Q1 2024.
  • Credit Suisse sold 362 Axsome Therapeutics shares in Q1 2024, an estimated $30.4K.
  • Axsome Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1506 holding.
  • Credit Suisse first reported a position in Axsome Therapeutics in Q2 2017 and has held it in 21 quarters since.
  • Credit Suisse's Axsome Therapeutics position peaked at $4.62M in Q4 2021.
  • 260 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.